Cargando…

Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis

Mounting evidence suggests that microbiota dysbiosis caused by antibiotic administration is a risk factor for cancer, but few research reports focus on the relationships between antibiotics and chemotherapy efficiency. We evaluated the influence of antibiotic administration on neoadjuvant therapy ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi, Yu, Long, Shi, Jiajie, Li, Sainan, Yang, Shiwei, Gao, Wei, Yang, Shan, Cheng, Meng, Wang, Haoqi, Guo, Zhanjun, Geng, Cuizhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263554/
https://www.ncbi.nlm.nih.gov/pubmed/34234229
http://dx.doi.org/10.1038/s41598-021-93428-w
_version_ 1783719408295739392
author Zhang, Xi
Yu, Long
Shi, Jiajie
Li, Sainan
Yang, Shiwei
Gao, Wei
Yang, Shan
Cheng, Meng
Wang, Haoqi
Guo, Zhanjun
Geng, Cuizhi
author_facet Zhang, Xi
Yu, Long
Shi, Jiajie
Li, Sainan
Yang, Shiwei
Gao, Wei
Yang, Shan
Cheng, Meng
Wang, Haoqi
Guo, Zhanjun
Geng, Cuizhi
author_sort Zhang, Xi
collection PubMed
description Mounting evidence suggests that microbiota dysbiosis caused by antibiotic administration is a risk factor for cancer, but few research reports focus on the relationships between antibiotics and chemotherapy efficiency. We evaluated the influence of antibiotic administration on neoadjuvant therapy efficacy in patients with breast cancer (BC) in the present study. BC patients were stratified into two groups: antibiotic-treated and control based on antibiotic administration within 30 days after neoadjuvant therapy initiation. Disease-free survival (DFS) and overall survival (OS) were assessed using the Kaplan–Meier method, and the Cox proportional hazards model was used for multivariate analyses. The pathologic complete response rate of the control group was significantly higher than that of the antibiotic-treated group (29.09% vs. 10.20%, p = 0.017). Further univariate analysis with Kaplan–Meier calculations demonstrated that antibiotic administration was strongly linked with both reduced DFS (p = 0.04) at significant statistical levels and OS (p = 0.088) at borderline statistical levels. Antibiotic administration was identified as a significant independent prognostic factor for DFS [hazard ratio (HR) 3.026, 95%, confidence interval (CI) 1.314–6.969, p = 0.009] and OS (HR 2.836, 95% CI 1.016–7.858, p = 0.047) by Cox proportional hazards model analysis. Antibiotics that initiated reduced efficiency of chemotherapy were more noticeable in the HER2-positive subgroup for both DFS (HR 5.51, 95% CI 1.77–17.2, p = 0.003) and OS (HR 7.0395% CI 1.94–25.53, p = 0.003), as well as in the T3-4 subgroup for both DFS (HR 20.36, 95% CI 2.41–172.07, p = 0.006) and OS (HR 13.45, 95% CI 1.39–130.08, p = 0.025) by stratified analysis. Antibiotic administration might be associated with reduced efficacy of neoadjuvant therapy and poor prognosis in BC patients. As a preliminary study, our research made preparations for further understanding and large-scale analyses of the impact of antibiotics on the efficacy of neoadjuvant therapy.
format Online
Article
Text
id pubmed-8263554
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82635542021-07-09 Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis Zhang, Xi Yu, Long Shi, Jiajie Li, Sainan Yang, Shiwei Gao, Wei Yang, Shan Cheng, Meng Wang, Haoqi Guo, Zhanjun Geng, Cuizhi Sci Rep Article Mounting evidence suggests that microbiota dysbiosis caused by antibiotic administration is a risk factor for cancer, but few research reports focus on the relationships between antibiotics and chemotherapy efficiency. We evaluated the influence of antibiotic administration on neoadjuvant therapy efficacy in patients with breast cancer (BC) in the present study. BC patients were stratified into two groups: antibiotic-treated and control based on antibiotic administration within 30 days after neoadjuvant therapy initiation. Disease-free survival (DFS) and overall survival (OS) were assessed using the Kaplan–Meier method, and the Cox proportional hazards model was used for multivariate analyses. The pathologic complete response rate of the control group was significantly higher than that of the antibiotic-treated group (29.09% vs. 10.20%, p = 0.017). Further univariate analysis with Kaplan–Meier calculations demonstrated that antibiotic administration was strongly linked with both reduced DFS (p = 0.04) at significant statistical levels and OS (p = 0.088) at borderline statistical levels. Antibiotic administration was identified as a significant independent prognostic factor for DFS [hazard ratio (HR) 3.026, 95%, confidence interval (CI) 1.314–6.969, p = 0.009] and OS (HR 2.836, 95% CI 1.016–7.858, p = 0.047) by Cox proportional hazards model analysis. Antibiotics that initiated reduced efficiency of chemotherapy were more noticeable in the HER2-positive subgroup for both DFS (HR 5.51, 95% CI 1.77–17.2, p = 0.003) and OS (HR 7.0395% CI 1.94–25.53, p = 0.003), as well as in the T3-4 subgroup for both DFS (HR 20.36, 95% CI 2.41–172.07, p = 0.006) and OS (HR 13.45, 95% CI 1.39–130.08, p = 0.025) by stratified analysis. Antibiotic administration might be associated with reduced efficacy of neoadjuvant therapy and poor prognosis in BC patients. As a preliminary study, our research made preparations for further understanding and large-scale analyses of the impact of antibiotics on the efficacy of neoadjuvant therapy. Nature Publishing Group UK 2021-07-07 /pmc/articles/PMC8263554/ /pubmed/34234229 http://dx.doi.org/10.1038/s41598-021-93428-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhang, Xi
Yu, Long
Shi, Jiajie
Li, Sainan
Yang, Shiwei
Gao, Wei
Yang, Shan
Cheng, Meng
Wang, Haoqi
Guo, Zhanjun
Geng, Cuizhi
Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis
title Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis
title_full Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis
title_fullStr Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis
title_full_unstemmed Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis
title_short Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis
title_sort antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263554/
https://www.ncbi.nlm.nih.gov/pubmed/34234229
http://dx.doi.org/10.1038/s41598-021-93428-w
work_keys_str_mv AT zhangxi antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT yulong antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT shijiajie antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT lisainan antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT yangshiwei antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT gaowei antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT yangshan antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT chengmeng antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT wanghaoqi antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT guozhanjun antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis
AT gengcuizhi antibioticsmodulateneoadjuvanttherapyefficiencyinpatientswithbreastcancerapilotanalysis